scout
|Videos|October 5, 2017

Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non—small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME